Industry
Hantavirus fears revive COVID-19 beneficiary stocks; Moderna and BioNTech in focus
Rising concerns about a possible spread of hantavirus are pushing medical and vaccine-related stocks back into focus after gaining attention during the COVID-19 pandemic. BeInCrypto reported that Moderna, Emergent BioSolutions and BioNTech entered reassessment phases in May. Moderna shares rose on stronger first-quarter sales, vaccine cooperation news and flu vaccine trial data publication. Emergent is focused on confirming a bottom amid weaker guidance. BioNTech faces a bearish technical pattern despite maintained revenue guidance.
